Skip to content

A clinical trial on Vasambu Chooranam in the management of Erigunmam (PEPTIC ULCER DISEASE)

A PROSPECTIVE OPEN LABELLED,NON-RANDOMIZED,PHASE II CLINICAL TRIAL OF VASAMBU CHOORANAM IN THE MANAGEMENT OF ERI GUNMAM (PEPTIC ULCER DISEASE)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/040375
Enrollment
40
Registered
2022-02-17
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K279- Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation

Interventions

Intervention1: VASAMBU CHOORANAM: 0.5g - 1g twice a day (orally) A/F 45 days along with honey as adjuvant Control Intervention1: NIL: NIL

Sponsors

Government Siddha Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients having symptoms of epigastric pain,heart burn,nausea,vomiting,loss of weight,water brash, indigestion and bloating of abdomen 2.Patients who are willing to take upper gastrointestinal endoscopy 3.Patients who are willing to give blood specimen and laboratory investigation when required

Exclusion criteria

Exclusion criteria: 1.Pregnancy 2.lactating mother 3.Diabetes Mellitus 4.Recent malignancy or radiation therapy 5.Gastro esophageal reflux disease 6.Pancreatitis 7.Inflammatory Bowel Disease 8.Acute hepatitis

Design outcomes

Primary

MeasureTime frame
If during treatment or after treatment reduction of the following symptoms 1.Epigastric pain 2.heart burn 3.nausea 4.vomiting 5.water brash 6.loss of weight 7.indigestion 8.bloating of abdomenTimepoint: 45 days

Secondary

MeasureTime frame
To evaluate the biochemical and physio-chemical and phytochemical analysis of clinical trial drug To evaluate the antimicrobial activity of trial drug To evaluate the safety profile for acute and sub acute toxicity of the trial drug Vasambu Chooranam To evaluate pharmacological analysis of the clinical trial drug To evaluate siddha parameters and modern parameters during the treatment of Peptic Ulcer Disease with trial drug To evaluate the statistical analysis of the clinical trial drug Vasambu Chooranam To evaluate the powder microscopic study and HTPLC of the trial drugTimepoint: 45 days

Countries

India

Contacts

Public ContactProf Dr A Manoharan MD s PhD

Government Siddha Medical College and Hospital Palayamkottai

drmanoharan25@gmail.com9443886700

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026